MEDXF News and Press, Medexus Pharmaceuticals Inc From 08/09/22

Medexus Pharmaceuticals Inc. (MEDXF) Q1 2023 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Ken d’Entremont - CEO Marcel Konrad - CFO Conference Call Participants Justin Keywoo...

Medexus Pharmaceuticals press release ( OTCQX:MEDXF ): Q1 Revenue of C$23M (+32.9% Y/Y). Generated Adjusted Net Loss of C$3.6 million in fiscal Q1 2023, a C$6.2 million improvement compared to C$9.8 million in fiscal Q1 2022. For furthe...

Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023 Management to host conference call at 8:00 AM Eastern Time on Tuesday, Au...

TORONTO and CHICAGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 9, 2022 to discuss Medexus’s results for its first quarter e...

Medexus Pharmaceuticals ( OTCQX:MEDXF ) its German partner medac resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for treosulfan following FDA's request for additional information related to the resubmitted NDA filed in April thi...

FDA decision expected within six months of acceptance Pivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO and CHICAGO, July 25, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: ...

Medexus Pharmaceuticals Inc. (MEDXF) Q4 2022 Earnings Conference Call June 23, 2022 8:00 am ET Company Participants Ken d’Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Officer Victoria Rutherford - Investor Relations, Adelaide Capital Conference Call Participants ...

Medexus Pharmaceuticals press release (OTCQX:MEDXF): Q4 Revenue of $20.3M (+15.3% Y/Y) beats by $1.54M. Achieved adjusted EBITDA of $1.1M in fiscal Q4 2022 compared to -$1.6M in fiscal Q4 2021 and $1.9M in fiscal Q3 2022. Generated adjusted net loss of $4.6M in fiscal ...

TORONTO and CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March&#x...

TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022 to discuss Medexus’s results for its fourth quarter ...